Literature DB >> 18031874

Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.

Saumyabrata Mazumder1, Rajesh Ravindran, Antara Banerjee, Nahid Ali.   

Abstract

The difficulty in making successful vaccines against leishmaniasis is partly due to lack of an appropriate adjuvant. Non-coding plasmid DNA (pDNA) bearing immunostimulatory sequences (ISS) is a potent activator of innate immunity, and can thus act as an adjuvant with vaccine antigen. We therefore evaluated the efficacy of pDNA and soluble leishmanial antigens (SLA) to protect against challenge with Leishmania donovani infection. We demonstrate that immunomodulatory activity of pDNA, which potentiated a Th1 immune responses, led to enhanced protection with SLA. Importantly, adding cationic liposomes as vehicle to the antigen, with pDNA either complexed or entrapped within, significantly increased the potentiating effect of pDNA. Further, comparison of the two vaccine formulations demonstrated an impressive increase in the protective efficacy up to two folds when both antigen and pDNA were within the vehicle. Thus, these studies establish the utility of non-coding pDNA bearing ISS as strong promoters of vaccine potency of liposomal antigens especially when co-entrapped with the antigen in cationic liposomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031874     DOI: 10.1016/j.vaccine.2007.10.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

2.  Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.

Authors:  Vahid Heravi Shargh; Mahmoud Reza Jaafari; Ali Khamesipour; Seyed Amir Jalali; Hengameh Firouzmand; Azam Abbasi; Ali Badiee
Journal:  Parasitol Res       Date:  2012-01-06       Impact factor: 2.289

3.  Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.

Authors:  Saumyabrata Mazumder; Mithun Maji; Nahid Ali
Journal:  PLoS Negl Trop Dis       Date:  2011-12-20

4.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

5.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

6.  Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice.

Authors:  Omid Chavoshian; Nazanin Biari; Ali Badiee; Ali Khamesipour; Azam Abbasi; Zahra Saberi; Seyed Amir Jalali; Mahmoud Reza Jaafari
Journal:  Iran J Basic Med Sci       Date:  2013-09       Impact factor: 2.699

Review 7.  Possibilities and challenges for developing a successful vaccine for leishmaniasis.

Authors:  Saumya Srivastava; Prem Shankar; Jyotsna Mishra; Sarman Singh
Journal:  Parasit Vectors       Date:  2016-05-12       Impact factor: 3.876

8.  Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.

Authors:  Abdus Sabur; Sudipta Bhowmick; Rudra Chhajer; Sarfaraz Ahmad Ejazi; Nicky Didwania; Mohammad Asad; Anirban Bhattacharyya; Utsa Sinha; Nahid Ali
Journal:  Front Immunol       Date:  2018-01-30       Impact factor: 7.561

Review 9.  Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.

Authors:  Sumit Joshi; Keerti Rawat; Narendra Kumar Yadav; Vikash Kumar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  Front Immunol       Date:  2014-08-22       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.